Alison Weiss

Alison A. Weiss

Professor

Medical Sciences Building

2254

COM Mol Gen Weiss Lab - 0524

Office 2254 Medical Sciences Building
231 Albert Sabin Way
Cincinnati, Ohio 45267

Professional Summary

The Weiss lab focuses on host-pathogen interactions with regard to infectious diarrhea.  We have employed a new experimental model to study enteric pathogens, pluripotent stem cell “induced human intestinal organoids” (iHIOs).  These “mini-guts” faithfully represent differentiated human intestinal tissue.  We have successfully used iHIOs to model human intestinal responses to bacterial infection and toxins, including E. coli O157:H7, Shiga toxin, C. difficile toxins, and microcystin (blue-green algae toxin).
 
Recently we have extended these studies to examine intestinal toxicity due to cytotoxic chemotherapy.  An estimated 16% of cancer and transplant patients receiving chemotherapy develop bloodstream infections due to mucosal barrier injury, despite almost universal use of antibiotic prophylaxis.  Toxigenic C. difficile infection is also common.  We are using human intestinal organoids to examine the interplay between the host intestinal tract and the human microbiome following cytotoxic chemotherapy treatment.   

Education

A.B., Washington University St. Louis,MO, 1975 (Biology)

M.S., University of Washington Seattle, WA, 1981 (Microbiology)

Ph.D., Stanford University Stanford, CA, 1983 (Medical Microbiology)

Positions and Work Experience

1985 -1993 Assistant/Associate Professor, Virginia Commonwealth University, Richmond, VA

1993 -2000 Associate Professor Molecular Genetics, University of Cincinnati, Cincinnati, OH

2000 -To Present Professor, Molecular Genetics, University of Cincinnati, Cincinnati, OH

Research and Practice Interests

Whooping cough remains an unconquered disease, worldwide. Developing nations simply do not have the resources to vaccinate their children. Very little disease is seen in the United States, and this is entirely due to the use of the whole-cell vaccine. However, this situation could change rapidly if the population refused to except the current whole cell vaccine, a situation which occurred in Great Britain and Sweden, where concern about the safety of this vaccine has lead to a decline of its use, and a subsequent rise in disease. The current whole cell vaccine contains only whole killed bacteria. A component vaccine of known composition would be desirable. The problem in developing a new component vaccine is to define what is necessary and sufficient to induce a protective immune response. We have focussed our efforts on trying to understand the disease, hoping to develop a theoretical basis for vaccine development. A unique aspect of the biology of Bordetella pertussis makes it an ideal model system to study pathogenesis. All of the genes required for virulence perhaps 20, are coordinately expressed and regulated by the growth conditions. All are expressed at 37degrees C the temperature of the human host but not at 25 degrees C Also, high concentrationsof MgSO4 can repress the synthesis of the virulence genes at 37 degrees C. We have shown that one gene called vir for virulence-regulating acts as a positive transcriptional inducer for the expression of the virulence genes. We propose to identify thesegene products necessary for the virulent state and to study their role in the disease. Previously, mutants were identified using transposon Tn5 lac, a derivative of Tn5 which retains the transposition functions, kanamycin resistance, and a ''reporter'' gene, the gene for Beta- galactosidase Beta-gal, without a functional promoter. Expression of Beta-gal occurs only when Tn5 lac has inserted into a functional gene. Tn5 lac insertions in the vir-regulated genes of B pertussis were identified as kanamycin-resistant mutants that express Beta-gal when the vir-regulated genes are on, but not when the vir-regulated genes are off. In the current proposal we will continue to identify and characterize the virulence factors of Bordetella pertussis, both geneticallyand for their role in the disease.

Research Support

Grant: #T32 AI055406 Investigators:Weiss, Alison 08-01-2003 -07-31-2009 National Institute of Allergy and Infectious Diseases Training in Biological Threat Agents Role:PI $1,519,310.00 Closed Level:Federal

Grant: #26020/5-30226 / U54 AI57153 Investigators:Weiss, Alison 03-01-2004 -02-28-2009 National Institute of Allergy and Infectious Diseases Antibody Neutralization of Anthrax Toxin Role:PI $598,330.00 Closed Level:Federal

Grant: #R01 AI064893 Investigators:Weiss, Alison 03-01-2007 -02-28-2013 National Institute of Allergy and Infectious Diseases Shiga Toxin Production and Role in Pathogenesis Role:PI $1,870,900.00 Active Level:Federal

Grant: #CHMC 499 / U38 CCU522352 Investigators:Weiss, Alison 09-30-2005 -09-29-2007 Centers for Disease Control and Prevention Role of Filamentous Hemagglutinin (FHA) in Disease and Protection from Pertussis Role:PI $283,542.00 Closed Level:Federal

Grant: #5-R21-AI-054762-02-A0-S0-E0 Investigators:Weiss, Alison 02-15-2003 -01-31-2005 National Institute of Allergy and Infectious Diseases Shiga Toxin Encoding Phage and Intestinal E. Coli Role:PI $411,409.00 Closed Level:Federal

Investigators:Weiss, Alison 10-27-2003 -03-31-2006 National Institute of Allergy and Infectious Diseases Evaluation of Control Measures Against Infectious Diseases Other than AIDS Role:PI $269,948.00 Closed Level:Federal

Grant: #5-R01-AI-45715-05-A0-S0-E0 Investigators:Weiss, Alison 07-01-2000 -05-31-2006 National Institute of Allergy and Infectious Diseases Human Serum and Protection Against Bordetella Pertussis Role:PI $1,329,225.00 Closed Level:Federal

Investigators:Weiss, Alison 07-01-2001 -05-31-2007 National Institute of Allergy and Infectious Diseases Biogenesis of Pertussis Toxin Role:PI $1,498,448.00 Closed Level:Federal

Grant: #5-R01-AI-23695-14-A0-S0-E0 Investigators:Weiss, Alison 07-01-1996 -06-30-2001 National Institute of Allergy and Infectious Diseases Characterization of the Pertussis Toxin Secretion Operon Role:PI $1,094,139.00 Closed Level:Federal

Grant: #5-R01-AI-38415-04-A0-S0-E0 Investigators:Weiss, Alison 01-01-1997 -12-31-2001 National Institute of Allergy and Infectious Diseases Complement Resistance in Bordetella Pertussis Role:PI $631,264.00 Closed Level:Federal

Grant: #U01 AI075498 Investigators:Iyer, Suri; Weiss, Alison 08-01-2007 -07-31-2013 National Institute of Allergy and Infectious Diseases Glycoconjugate Based Diagnostics for Bacterical Toxins Role:PI $1,976,698.00 Active Level:Federal

Grant: #R56 AI023695 Investigators:Miller, William; Monaco, John; Weiss, Alison 08-01-2008 -07-31-2009 National Institute of Allergy and Infectious Diseases Biologic Activities of the Pertusis Toxin B-Pentamer Role:PI $351,000.00 Closed Level:Federal

Grant: #2 R01 AI023695-20A1 Investigators:Miller, William; Monaco, John; Weiss, Alison 09-01-2009 -08-31-2012 National Institute of Allergy and Infectious Diseases Biologic Activities of the Pertusis Toxin B-Pentamer Role:PI $706,500.00 Active Level:Federal

Grant: #R01 AI089450 Investigators:Iyer, Suri; Weiss, Alison 05-15-2010 -04-30-2015 National Institute of Allergy and Infectious Diseases Glycan Receptor Mimics for Rapid Detection, Typing, and Susceptibility Testing of Influenza Role:PI $1,227,961.00 Active Level:Federal

Grant: #SRS 006920 Investigators:Gunasekera, Thusitha; Weiss, Alison 03-23-2010 -12-24-2011 Department of Energy ORISE Role:PI $112,430.00 Closed Level:Federal

Grant: #U19 AI116491 Investigators:Hong, Christian; Moore, Sean; Weiss, Alison; Wells, James; Zavros, Yana 03-01-2015 -02-29-2020 National Institute of Allergy and Infectious Diseases Organoids as a Model System for Studying Gastrointestinal Disease Role:PI $931,304.00 Awarded Level:Federal

Grant: #R01 AI139027-01 Investigators:Alison Weiss 08-2018 -07-2022 NIH-NIAID MICROBIOME AND E. COLI O157:H7 INFECTION OF HUMAN GUT TISSUE Role:PI $400,104 Active Type:Grant

Grant: #R21AI115003 Investigators:Weiss, Alison 08-19-2016 -07-31-2018 National Institute of Allergy and Infectious Diseases Shiga toxin activity in human intestinal organoids Role:PI $237,188.00 Active Level:Federal

Grant: #R01 AI139027 Investigators:Weiss, Alison 08-15-2018 -07-31-2022 National Institute of Allergy and Infectious Diseases Microbiome and E. coli O157:H7 infection of human gut tissue Role:PI $400,104.00 Active Level:Federal

Grant: #302328 / R01DK114123 Investigators:Weiss, Alison 05-01-2018 -04-30-2023 National Inst of Diabetes and Digestive and Kidney Disease Epigenomic control of antimicrobial immunity in the intestine Role:PI $14,653.00 Awarded Level:Federal

Publications

Peer Reviewed Publications

Schneider, Olivia D; Millen, Scott H; Weiss, Alison A; Miller, William E (2012. )Mechanistic insight into pertussis toxin and lectin signaling using T cells engineered to express a CD8?/CD3? chimeric receptor.Biochemistry, ,51 (20 ),4126-37

Gallegos, Karen M; Conrady, Deborah G; Karve, Sayali S; Gunasekera, Thusitha S; Herr, Andrew B; Weiss, Alison A (2012. )Shiga toxin binding to glycolipids and glycans.PloS one, ,7 (2 ),e30368

Archdeacon, Michael T; Kazemi, Namdar; Romanowski, James R; Mobberley-Schuman, Paula S; Weiss, Alison A (2011. )Reaming as an adjuvant to irrigation on bacterial presence and propagation: an open, cadaveric intramedullary fracture model.Journal of orthopaedic trauma, ,25 (6 ),325-30

Fuller, Cynthia A; Pellino, Christine A; Flagler, Michael J; Strasser, Jane E; Weiss, Alison A (2011. )Shiga toxin subtypes display dramatic differences in potency.Infection and immunity, ,79 (3 ),1329-37

Conrady, Deborah G; Flagler, Michael J; Friedmann, David R; Vander Wielen, Bradley D; Kovall, Rhett A; Weiss, Alison A; Herr, Andrew B (2010. )Molecular basis of differential B-pentamer stability of Shiga toxins 1 and 2.PloS one, ,5 (12 ),e15153

Kulkarni, Ashish A; Weiss, Alison A; Iyer, Suri S (2010. )Detection of carbohydrate binding proteins using magnetic relaxation switches.Analytical chemistry, ,82 (17 ),7430-5

Kulkarni, Ashish A; Fuller, Cynthia; Korman, Henry; Weiss, Alison A; Iyer, Suri S (2010. )Glycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2.Bioconjugate chemistry, ,21 (8 ),1486-93

Millen, Scott H; Lewallen, Daniel M; Herr, Andrew B; Iyer, Suri S; Weiss, Alison A (2010. )Identification and characterization of the carbohydrate ligands recognized by pertussis toxin via a glycan microarray and surface plasmon resonance.Biochemistry, ,49 (28 ),5954-67

Flagler, Michael J; Mahajan, Sujit S; Kulkarni, Ashish A; Iyer, Suri S; Weiss, Alison A (2010. )Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2.Biochemistry, ,49 (8 ),1649-57

Kulkarni, Ashish A; Weiss, Alison A; Iyer, Suri S (2010. )Glycan-based high-affinity ligands for toxins and pathogen receptors.Medicinal research reviews, ,30 (2 ),327-93

Schneider, Olivia D; Weiss, Alison A; Miller, William E (2009. )Pertussis toxin signals through the TCR to initiate cross-desensitization of the chemokine receptor CXCR4.Journal of immunology (Baltimore, Md. : 1950), ,182 (9 ),5730-9

Conrady, Deborah G; Brescia, Cristin C; Horii, Katsunori; Weiss, Alison A; Hassett, Daniel J; Herr, Andrew B (2008. )A zinc-dependent adhesion module is responsible for intercellular adhesion in staphylococcal biofilms.Proceedings of the National Academy of Sciences of the United States of America, ,105 (49 ),19456-61

Hatch, Duane M; Weiss, Alison A; Kale, Ramesh R; Iyer, Suri S (2008. )Biotinylated bi- and tetra-antennary glycoconjugates for Escherichia coli detection.Chembiochem : a European journal of chemical biology, ,9 (15 ),2433-42

Taft, Sarah C; Weiss, Alison A (2008. )Toxicity of anthrax toxin is influenced by receptor expression.Clinical and vaccine immunology : CVI, ,15 (9 ),1330-6

Kale, Ramesh R; McGannon, Colleen M; Fuller-Schaefer, Cynthia; Hatch, Duane M; Flagler, Michael J; Gamage, Shantini D; Weiss, Alison A; Iyer, Suri S (2008. )Differentiation between structurally homologous Shiga 1 and Shiga 2 toxins by using synthetic glycoconjugates.Angewandte Chemie (International ed. in English), ,47 (7 ),1265-8

Taft, Sarah C; Weiss, Alison A (2008. )Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.Clinical and vaccine immunology : CVI, ,15 (1 ),71-5

Schneider, Olivia D; Weiss, Alison A; Miller, William E (2007. )Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells.Infection and immunity, ,75 (8 ),4040-9

Flagler, Michael J; Strasser, Jane E; Chalk, Claudia L; Weiss, Alison A (2007. )Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis.Infection and immunity, ,75 (2 ),760-5

Watanabe, Mineo; Connelly, Beverly; Weiss, Alison A (2006. )Characterization of serological responses to pertussis.Clinical and vaccine immunology : CVI, ,13 (3 ),341-8

Gamage, Shantini D; Patton, Angela K; Strasser, Jane E; Chalk, Claudia L; Weiss, Alison A (2006. )Commensal bacteria influence Escherichia coli O157:H7 persistence and Shiga toxin production in the mouse intestine.Infection and immunity, ,74 (3 ),1977-83

Hanson, James F; Taft, Sarah C; Weiss, Alison A (2006. )Neutralizing antibodies and persistence of immunity following anthrax vaccination.Clinical and vaccine immunology : CVI, ,13 (2 ),208-13

Mobberley-Schuman, Paula S; Weiss, Alison A (2005. )Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils.Infection and immunity, ,73 (11 ),7317-23

Weiss, Alison A; Patton, Angela K; Millen, Scott H; Chang, Swei-Ju; Ward, Joel I; Bernstein, David I (2004. )Acellular pertussis vaccines and complement killing of Bordetella pertussis.Infection and immunity, ,72 (12 ),7346-51

Gamage, Shantini D; Patton, Angela K; Hanson, James F; Weiss, Alison A (2004. )Diversity and host range of Shiga toxin-encoding phage.Infection and immunity, ,72 (12 ),7131-9

Schaeffer, Lyndsay M; McCormack, Francis X; Wu, Huixing; Weiss, Alison A (2004. )Interactions of pulmonary collectins with Bordetella bronchiseptica and Bordetella pertussis lipopolysaccharide elucidate the structural basis of their antimicrobial activities.Infection and immunity, ,72 (12 ),7124-30

Gamage, Shantini D; McGannon, Colleen M; Weiss, Alison A (2004. )Escherichia coli serogroup O107/O117 lipopolysaccharide binds and neutralizes Shiga toxin 2.Journal of bacteriology, ,186 (16 ),5506-12

Schaeffer, Lyndsay M; McCormack, Francis X; Wu, Huixing; Weiss, Alison A (2004. )Bordetella pertussis lipopolysaccharide resists the bactericidal effects of pulmonary surfactant protein A. Journal of immunology (Baltimore, Md. : 1950), ,173 (3 ),1959-65

Millen, Scott H; Bernstein, David I; Connelly, Beverly; Ward, Joel I; Chang, Swei-Ju; Weiss, Alison A (2004. )Antibody-mediated neutralization of pertussis toxin-induced mitogenicity of human peripheral blood mononuclear cells. Infection and immunity, ,72 (1 ),615-20

Rambow-Larsen, Amy A; Weiss, Alison A (2004. )Temporal expression of pertussis toxin and Ptl secretion proteins by Bordetella pertussis. Journal of bacteriology, ,186 (1 ),43-50

Gamage, Shantini D; Strasser, Jane E; Chalk, Claudia L; Weiss, Alison A (2003. )Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infection and immunity, ,71 (6 ),3107-15

Mobberley-Schuman, Paula S; Connelly, Beverly; Weiss, Alison A (2003. )Phagocytosis of Bordetella pertussis incubated with convalescent serum.The Journal of infectious diseases, ,187 (10 ),1646-53

Barnes, Michael G; Weiss, Alison A (2003. )Activation of the complement cascade by Bordetella pertussis. FEMS microbiology letters, ,220 (2 ),271-5

Stenson, Trevor H; Patton, Angela K; Weiss, Alison A (2003. )Reduced glutathione is required for pertussis toxin secretion by Bordetella pertussis. Infection and immunity, ,71 (3 ),1316-20

Rambow-Larsen, Amy A; Weiss, Alison A (2002. )The PtlE protein of Bordetella pertussis has peptidoglycanase activity required for Ptl-mediated pertussis toxin secretion. Journal of bacteriology, ,184 (11 ),2863-9

Stenson, Trevor H; Weiss, Alison A (2002. )DsbA and DsbC are required for secretion of pertussis toxin by Bordetella pertussis. Infection and immunity, ,70 (5 ),2297-303

Barnes, Michael G; Weiss, Alison A (2002. )Growth phase influences complement resistance of Bordetella pertussis. Infection and immunity, ,70 (1 ),403-6

Schaeffer, L M; Weiss, A A (2001. )Pertussis toxin and lipopolysaccharide influence phagocytosis of Bordetella pertussis by human monocytes.Infection and immunity, ,69 (12 ),7635-41

Barnes, M G; Weiss, A A (2001. )BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition.Infection and immunity, ,69 (5 ),3067-72

Weingart, C L; Keitel, W A; Edwards, K M; Weiss, A A (2000. )Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infection and immunity, ,68 (12 ),7175-9

Weingart, C L; Mobberley-Schuman, P S; Hewlett, E L; Gray, M C; Weiss, A A (2000. )Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infection and immunity, ,68 (12 ),7152-5

Craig-Mylius, K A; Weiss, A A (2000. )Antibacterial agents and release of periplasmic pertussis toxin from Bordetella pertussis. Antimicrobial agents and chemotherapy, ,44 (5 ),1383-6

Weingart, C L; Weiss, A A (2000. )Bordetella pertussis virulence factors affect phagocytosis by human neutrophils. Infection and immunity, ,68 (3 ),1735-9

Craig-Mylius, K A; Stenson, T H; Weiss, A A (2000. )Mutations in the S1 subunit of pertussis toxin that affect secretion. Infection and immunity, ,68 (3 ),1276-81

Lenz, D H; Weingart, C L; Weiss, A A (2000. )Phagocytosed Bordetella pertussis fails to survive in human neutrophils. Infection and immunity, ,68 (2 ),956-9

Craig-Mylius, K A; Weiss, A A (1999. )Mutants in the ptlA-H genes of Bordetella pertussis are deficient for pertussis toxin secretion. FEMS microbiology letters, ,179 (2 ),479-84

Weingart, C L; Broitman-Maduro, G; Dean, G; Newman, S; Peppler, M; Weiss, A A (1999. )Fluorescent labels influence phagocytosis of Bordetella pertussis by human neutrophils. Infection and immunity, ,67 (8 ),4264-7

Weiss, A A; Mobberley, P S; Fernandez, R C; Mink, C M (1999. )Characterization of human bactericidal antibodies to Bordetella pertussis. Infection and immunity, ,67 (3 ),1424-31

Rambow, A A; Fernandez, R C; Weiss, A A (1998. )Characterization of BrkA expression in Bordetella bronchiseptica. Infection and immunity, ,66 (8 ),3978-80

Fernandez, R C; Weiss, A A (1998. )Serum resistance in bvg-regulated mutants of Bordetella pertussis. FEMS microbiology letters, ,163 (1 ),57-63

Fernandez, R C; Weiss, A A (1996. )Susceptibilities of Bordetella pertussis strains to antimicrobial peptides. Antimicrobial agents and chemotherapy, ,40 (4 ),1041-3

Fernandez, R C; Weiss, A A (1995. )Cloning and sequencing of the Bordetella pertussis cpn10/cpn60 (groESL) homolog. Gene, ,158 (1 ),151-2

Fernandez, R C; Weiss, A A (1994. )Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infection and immunity, ,62 (11 ),4727-38

Walker, K E; Weiss, A A (1994. )Characterization of the dermonecrotic toxin in members of the genus Bordetella. Infection and immunity, ,62 (9 ),3817-28

Stibitz, S; Weiss, A A; Falkow, S (1988. )Genetic analysis of a region of the Bordetella pertussis chromosome encoding filamentous hemagglutinin and the pleiotropic regulatory locus vir. Journal of bacteriology, ,170 (7 ),2904-13

Steinman, L; Weiss, A; Adelman, N; Lim, M; Zuniga, R; Oehlert, J; Hewlett, E; Falkow, S (1985. )Pertussis toxin is required for pertussis vaccine encephalopathy. Proceedings of the National Academy of Sciences of the United States of America, ,82 (24 ),8733-6

Steinman, L; Weiss, A; Adelman, N; Lim, M; Oehlert, J; Zuniga, R; Hewlett, E; Falkow, S (1985. )Murine model for pertussis vaccine encephalopathy: role of the major histocompatibility complex; antibody to albumin and to Bordetella pertussis and pertussis toxin. Developments in biological standardization, ,61 ,439-46

Weiss, A A; Hewlett, E L; Myers, G A; Falkow, S (1985. )Genetic studies of the molecular basis of whooping cough. Developments in biological standardization, ,61 ,11-9

Weiss, A A; Hewlett, E L; Myers, G A; Falkow, S (1984. )Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis. The Journal of infectious diseases, ,150 (2 ),219-22

Weiss, A A; Falkow, S (1984. )Genetic analysis of phase change in Bordetella pertussis. Infection and immunity, ,43 (1 ),263-9

Weiss, A A; Hewlett, E L; Myers, G A; Falkow, S (1983. )Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infection and immunity, ,42 (1 ),33-41

Weiss, A A; Falkow, S (1983. )Transposon insertion and subsequent donor formation promoted by Tn501 in Bordetella pertussis. Journal of bacteriology, ,153 (1 ),304-9

Weiss, A A; Falkow, S (1982. )Plasmid transfer to Bordetella pertussis: conjugation and transformation. Journal of bacteriology, ,152 (1 ),549-52

Hewlett, E L; Gray, M C; Ehrmann, I E; Maloney, N J; Otero, A S; Gray, L; Allietta, M; Szabo, G; Weiss, A A; Barry, E M (1993. )Characterization of adenylate cyclase toxin from a mutant of Bordetella pertussis defective in the activator gene, cyaC. The Journal of biological chemistry, ,268 (11 ),7842-8

Ehrmann, I E; Weiss, A A; Goodwin, M S; Gray, M C; Barry, E; Hewlett, E L (1992. )Enzymatic activity of adenylate cyclase toxin from Bordetella pertussis is not required for hemolysis. FEBS letters, ,304 (1 ),51-6

Barry, E M; Weiss, A A; Ehrmann, I E; Gray, M C; Hewlett, E L; Goodwin, M S (1991. )Bordetella pertussis adenylate cyclase toxin and hemolytic activities require a second gene, cyaC, for activation. Journal of bacteriology, ,173 (2 ),720-6

Pearson, R D; Symes, P; Conboy, M; Weiss, A A; Hewlett, E L (1987. )Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin. Journal of immunology (Baltimore, Md. : 1950), ,139 (8 ),2749-54

Cronin, M J; Evans, W S; Rogol, A D; Weiss, A A; Thorner, M O; Orth, D N; Nicholson, W E; Yasumoto, T; Hewlett, E L (1986. )Prokaryotic adenylate cyclase toxin stimulates anterior pituitary cells in culture. The American journal of physiology, ,251 (2 Pt 1 ),E164-71

Weiss, A A; Hewlett, E L (1986. )Virulence factors of Bordetella pertussis.Annual review of microbiology, ,40 ,661-86

Hewlett, E L; Weiss, A A; Crane, J K; Pearson, R D; Anderson, H J; Myers, G A; Evans, W S; Hantske, L L; Kay, H D; Cronin, M J (1985. )Bordetella extracytoplasmic adenylate cyclase: actions as a bacterial toxin. Developments in biological standardization, ,61 ,21-6

Lee, C., M.A. Gaston, A.A. Weiss, and P. Zhang (2013. ). Colorimetric viral detection based on sialic acid stabilized gold nanoparticles. Biosensor. Bioelectronic, ,236 -236-241

Yosief, H.O., A.A. Weiss and S.S. Iyer (2013. )Capture of uropathogenic Escherichia coli using synthetic glycan ligands specific for the Pap-pilus. .ChemBioChem, ,14 , -251–259

Yosief, H.O., S.S. Iyer, and A.A. Weiss (2013. )Binding of Pk-trisaccharide analogs of Globotriaosylceramide to Shiga toxin variants. Infect. Immun, ,81 , -2753-2760

Millen SH, Schneider OD, Miller WE, Monaco JJ, Weiss AA (2013. )Pertussis Toxin B-Pentamer Mediates Intercellular Transfer of Membrane Proteins and Lipids. .PLoS ONE , ,8(9): , -e72885

Gaston MA, Pellino CA, Weiss AA (2013. )Failure of Manganese to Protect from Shiga Toxin. .PLoS ONE , ,8(7): e69823 ,

Karve, SS and AA Weiss (2014. )Glycolipid Binding Preferences of Shiga Toxin Variants .PLoS ONE, ,9(7): e101173 ,

Goodwin M.S.M.;Weiss A.A. (01-01-1990. )Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infe .Infection and Immunity, ,58 (10 ),3445-3447

Weiss A.;St. Mary Goodwin M. (01-01-1989. )Lethal infection by Bordetella pertussis mutants in the infant mouse model .Infection and Immunity, ,57 (12 ),3757-3764

Melton A.;Weiss A. (01-01-1989. )Environmental regulation of expression of virulence determinants in Bordetella pertussis.Journal of Bacteriology, ,171 (11 ),6206-6212

Ewanowich C.;Melton A.;Weiss A.;Sherburne R.;Peppler M. (01-01-1989. )Invasion of HeLa 229 cells by virulent Bordetella pertussis .Infection and Immunity, ,57 (9 ),2698-2704

Weiss A.;Melton A.;Walker K.;Androaos-Selim C.;Meidl J. (01-01-1989. )Use of the promoter fusion transposon Tn5 lac to identify mutations in Bordetella pertussis vir-regu .Infection and Immunity, ,57 (9 ),2674-2682

Hoppe J.; Weiss A.; Worz S. (01-01-1988. )Failure of charcoal-horse-blood broth with cephalexin to significantly increase rate of Bordetella i .Journal of Clinical Microbiology, ,26 (6 ),1248-1249

Hoppe J.; Weiß A. (04-01-1987. )Recovery of Bordetella pertussis from four kinds of swabs.European Journal of Clinical Microbiology, ,6 (2 ),203-205

Tuomanen E.; Weiss A. (01-01-1985. )Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial c.Journal of Infectious Diseases, ,152 (1 ),118-125

Rich R.; Tuomanen E.; Weiss A. (01-01-1985. )Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia .Developments in Biological Standardization, ,VOL. 61 ,197-204

Steinman L.;Weiss A.;Adelman N.;Lim M.;Zuniga R.;Oehlert J.;Hewlett E.;Falkow S. (01-01-1985. )Pertussis toxin is required for pertussis vaccine encephalopathy.Proceedings of the National Academy of Sciences of the United States of America, ,82 (24 ),8733-8736

Karve S.;Pradhan S.;Ward D.;Weiss A. (06-01-2017. )Intestinal organoids model human responses to infection by commensal and Shiga toxin producing Esche.PLoS ONE, ,12 (6 ),

Lee C.;Wang P.;Gaston M.;Weiss A.;Zhang P. (01-01-2017. )Plasmonics-based detection of virus using sialic acid functionalized gold nanoparticles.Methods in Molecular Biology, ,1571 ,109-116

Murdock R.C.;Gallegos K.M.;Hagen J.A.;Kelley-Loughnane N.;Weiss A.A.;Papautsky I. (01-01-2017. )Development of a point-of-care diagnostic for influenza detection with antiviral treatment effective.Lab on a Chip, ,17 (2 ),332-340

Pradhan S.;Pellino C.;MacMaster K.;Coyle D.;Weiss A. (09-29-2016. )Shiga toxin mediated neurologic changes in murine model of disease.Frontiers in Cellular and Infection Microbiology, ,6 (SEP ),

Pellino C.;Karve S.;Pradhan S.;Weiss A. (06-01-2016. )AB5preassembly is not required for Shiga toxin activity.Journal of Bacteriology, ,198 (11 ),1621-1630

Millen S.H.;Watanabe M.;Komatsu E.;Yamaguchi F.;Nagasawa Y.;Suzuki E.;Monaco H.;Weiss A.A. (09-16-2015. )Single amino acid polymorphisms of pertussis toxin subunit S2 (PtxB) affect protein function.PLoS ONE, ,10 (9 ),

Karve S.;Weiss A. (07-01-2014. )Glycolipid binding preferences of shiga toxin variants.PLoS ONE, ,9 (7 ),

Millen S.;Schneider O.;Miller W.;Monaco J.;Weiss A. (09-03-2013. )Pertussis Toxin B-Pentamer Mediates Intercellular Transfer of Membrane Proteins and Lipids.PLoS ONE, ,8 (9 ),

Gaston M.;Pellino C.;Weiss A. (07-16-2013. )Failure of Manganese to Protect from Shiga Toxin.PLoS ONE, ,8 (7 ),

Lee C.;Gaston M.;Weiss A.;Zhang P. (04-05-2013. )Colorimetric viral detection based on sialic acid stabilized gold nanoparticles.Biosensors and Bioelectronics, ,42 (1 ),236-241

Yosief H.O.;Weiss A.A.;Iyer S.S. (01-01-2013. )Capture of Uropathogenic E. coli by Using Synthetic Glycan Ligands Specific for the Pap-Pilus.ChemBioChem, ,14 (2 ),251-259

Schneider O.;Millen S.;Weiss A.;Miller W. (05-22-2012. )Mechanistic insight into pertussis toxin and lectin signaling using t cells engineered to express a .Biochemistry, ,51 (20 ),4126-4137

Gallegos K.;Conrady D.;Karve S.;Gunasekera T.;Herr A.;Weiss A. (02-13-2012. )Shiga toxin binding to glycolipids and glycans.PLoS ONE, ,7 (2 ),

McGannon C.;Fuller C.;Weiss A. (09-01-2010. )Different classes of antibiotics differentially influence shiga toxin production.Antimicrobial Agents and Chemotherapy, ,54 (9 ),3790-3798

Komatsu E.;Yamaguchi F.;Abe A.;Weiss A.;Watanabe M. (05-01-2010. )Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular p.Clinical and Vaccine Immunology, ,17 (5 ),807-812

Weiss A.;Iyer S. (01-01-2007. )Glycomics aims to interpret the third molecular language of cells.Microbe, ,2 (10 ),489-497

Fisher J.; Kim K.; Kuzmenko A.; McCormack F.; Schaffer L.; Wan S.; Weiss A.; Wu H. (05-01-2003. )Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane perm .The Journal of clinical investigation, ,111 (10 ),1589-1602

Wu H.;Kuzmenko A.;Wan S.;Schaffer L.;Weiss A.;Fisher J.;Kim K.;McCormack F. (01-01-2003. )Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane perm.Journal of Clinical Investigation, ,111 (10 ),1589-1602

Temple L.M.;Weiss A.A.;Walker K.E.;Barnes H.J.;Christensen V.L.;Miyamoto D.M.;Shelton C.B.;Orndorff P.E. (12-01-1998. )Bordetella avium virulence measured in vivo and in vitro .Infection and Immunity, ,66 (11 ),5244-5251

Denko N.; Hudson K.; Lieberman M.; Oswald E.; Schwab E.; Weiss A. (11-01-1996. )Megakaryocytic cell line-specific hyperploidy by cytotoxic necrotizing factor bacterial toxins .Blood, ,88 (9 ),3465-3473

Melton A.;Weiss A. (01-01-1993. )Characterization of environmental regulators of Bordetella pertussis .Infection and Immunity, ,61 (3 ),807-815

Weiss A.;Johnson F.;Burns D. (01-01-1993. )Molecular characterization of an operon required for pertussis toxin secretion.Proceedings of the National Academy of Sciences of the United States of America, ,90 (7 ),2970-2974

Ehrmann I.;Weiss A.;Goodwin M.;Gray M.;Barry E.;Hewlett E. (01-01-1993. )Erratum: Enzymatic activity of adenylate cyclase toxins from Bordetella pertussis is not required fo.FEBS Letters, ,320 (1 ),86

Honors and Awards

1990 American Society for Microbiology, Foundation Lectureship

1987 -1991 Pew Scholar in the Biomedical Sciences

1984 -1985 Damon Runyon--Walter Winchell Postdoctoral Fellowship

1981 -1983 NIH Predoctoral Fellowship, Stanford University

1980 American Society for Microbiology, Presidents Fellowship

2010 Fellow of Graduate School, University of Cincinnati

2011 American Society for Microbiology mini-colloquium on E. coli

2013 Scientific and Programme Committee, 10th International Bordetella Symposium, Dublin, Ireland

2013 Elected American Academy of Microbiology

2014 American Society for Microbiology, Scientific Affairs Board, Committee on Biomedical Research

2006 Meeting Organizer “13th Annual Midwest Microbial Pathogenesis Conference

2014 External Program Reviewer, Department of Microbiology, Miami University

2008 -2012 Member Host Immunity, Bacterial Pathogensis study section, NIAID

2006 Session organizer and convener – ASM Annual Meeting “One Hundred Years of Pertussis (the Cough of One Hundred Days)”

1998 -2000 Councilor at Large, American Society for Microbiology

1995 -1996 Chair Elect and Chair Division B - Microbial Pathogenesis, American Soc. Microb.

Editorial Board, Infection and Immunity

2000 -2004 Merit Review Subcommittee for Infectious Diseases,

2000 -2004 Merit Review Subcommittee for Infectious Diseases, Veterans Administration

1993 -1997 Microbiology and Infectious Diseases Research Com.Study Section, NIAID

1998 Organizer - Symposium on Bordetella pertussis, A.S.M. Meeting

1996 Organizer - Symposium on Gram negative bacteria, A.S.M. Meeting

Post Graduate Training and Education

1983-1985 Postdoctoral Fellow, University of Virginia, ,Charlottesville, VA

Keywords

Mutant,Virulence,Disease Model,Gene Mutation,Bacterial Toxin,Molecular Cloning,Bacterial Genetics,Tissue Cell Culture,Bordetella Pertussis,Genetic Manipulation,Transposon Insertion Element,0157:H7,Shiga toxin,Pertussis Toxin,Bacterial Secretion,Complement,Vaccine,Microbiology

Contact Information

Academic - Office 2254 Medical Sciences Building
231 Albert Sabin Way
Cincinnati  Ohio, 45267
Phone: (513)558-2820
alison.weiss@uc.edu